Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Alzheimer's Disease | Research

Disease severity and mortality in Alzheimer's disease: an analysis using the U.S. National Alzheimer’s Coordinating Center Uniform Data Set

Authors: Valerie Crowell, Adriana Reyes, Summera Qiheng Zhou, Maria Vassilaki, Sandro Gsteiger, Anders Gustavsson

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Evidence on the relative risk of death across all stages of Alzheimer’s disease (AD) is lacking but greatly needed for the evaluation of new interventions. We used data from the Uniform Data Set (UDS) of the National Alzheimer’s Coordinating Center (NACC) to assess the expected survival of a person progressing to a particular stage of AD and the relative risk of death for a person in a particular stage of AD compared with cognitively normal (CN) people.

Methods

This was a retrospective observational cohort study of mortality and its determinants in participants with incident mild cognitive impairment (MCI) due to AD or AD dementia compared with CN participants. Overall survival and hazard ratios of all-cause mortality in participants ≥ 50 years of age with clinically assessed or diagnosed MCI due to AD, or mild, moderate, or severe AD dementia, confirmed by Clinical Dementia Rating scores, versus CN participants were estimated, using NACC UDS data. Participants were followed until death, censoring, or until information to determine disease stage was missing.

Results

Aged between 50 and 104 years, 12,414 participants met the eligibility criteria for the study. Participants progressing to MCI due to AD or AD dementia survived a median of 3–12 years, with higher mortality observed in more severe stages. Risk of death increased with the severity of AD dementia, with the increase significantly higher at younger ages. Participants with MCI due to AD and CN participants had a similar risk of death after controlling for confounding factors.

Conclusions

Relative all-cause mortality risk increases with AD severity, more so at younger ages. Mortality does not seem to be higher for those remaining in MCI due to AD. Findings might imply potential benefit of lower mortality if preventing or delaying the progression of AD is successful, and importantly, this potential benefit might be greater in relatively younger people. Future research should replicate our study in other samples more representative of the general US population as well as other populations around the world.
Appendix
Available only for authorised users
Literature
1.
Gustavsson A, Norton N, Fast T, Frolich L, Georges J, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimers Dement. 2023;19:658–70.PubMed
2.
Gustavsson A, Raket LL, Lilja M, Rutten-Jacobs L, Fues Wahl H, et al. Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study. Alzheimers Dement. 2021;17:1832–42.PubMed
3.
GBD Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88–106.
4.
5.
WHO. Global status report on the public health response to dementia. Geneva: World Health Organization,. 2021.
6.
Tochel C, Smith M, Baldwin H, Gustavsson A, Ly A, et al. What outcomes are important to patients with mild cognitive impairment or Alzheimer’s disease, their caregivers, and health-care professionals? A systematic review. Alzheimers Dement (Amst). 2019;11:231–47.PubMedPubMedCentral
7.
Janssen O, Vos SJB, Garcia-Negredo G, Tochel C, Gustavsson A, et al. Real-world evidence in Alzheimer’s disease: the ROADMAP Data Cube. Alzheimers Dement. 2020;16:461–71.PubMed
8.
Gustavsson A, Green C, Jones RW, Forstl H, Simsek D, et al. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease. Alzheimers Dement. 2017;13:312–21.PubMed
9.
Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013;28:1109–24.PubMed
10.
Strand BH, Knapskog AB, Persson K, Edwin TH, Amland R, et al. Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway. PLoS One. 2018;13: e0204436.PubMedPubMedCentral
11.
Guehne U, Riedel-Heller S, Angermeyer MC. Mortality in dementia. Neuroepidemiology. 2005;25:153–62.PubMed
12.
Brodaty H, Seeher K, Gibson L. Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia. Int Psychogeriatr. 2012;24:1034–45.PubMed
13.
Go SM, Lee KS, Seo SW, Chin J, Kang SJ, et al. Survival of Alzheimer’s disease patients in Korea. Dement Geriatr Cogn Disord. 2013;35:219–28.PubMed
14.
Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140:501–9.PubMed
15.
Mueller C, Huntley J, Stubbs B, Sommerlad A, Carvalho AF, et al. Associations of neuropsychiatric symptoms and antidepressant prescription with survival in Alzheimer’s disease. J Am Med Dir Assoc. 2017;18:1076–81.PubMed
16.
Ueki A, Shinjo H, Shimode H, Nakajima T, Morita Y. Factors associated with mortality in patients with early-onset Alzheimer’s disease: a five-year longitudinal study. Int J Geriatr Psychiatry. 2001;16:810–5.PubMed
17.
Liang FW, Chan W, Chen PJ, Zimmerman C, Waring S, et al. Cognitively-related basic activities of daily living impairment greatly increases the risk of death in Alzheimers disease. PLoS One. 2016;11: e0160671.PubMedPubMedCentral
18.
Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, et al. Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology. 2008;71:1489–95.PubMedPubMedCentral
19.
Xue H, Sun Q, Liu L, Zhou L, Liang R, et al. Risk factors of transition from mild cognitive impairment to Alzheimer’s disease and death: a cohort study. Compr Psychiatry. 2017;78:91–7.PubMed
20.
Cosentino S, Scarmeas N, Albert SM, Stern Y. Verbal fluency predicts mortality in Alzheimer disease. Cogn Behav Neurol. 2006;19:123–9.PubMedPubMedCentral
21.
Mehta KM, Yaffe K, Perez-Stable EJ, Stewart A, Barnes D, et al. Race/ethnic differences in AD survival in US Alzheimer’s Disease Centers. Neurology. 2008;70:1163–70.PubMed
22.
Jang H, Kim JH, Choi SH, Lee Y, Hong CH, et al. Body mass index and mortality rate in Korean patients with Alzheimer’s disease. J Alzheimers Dis. 2015;46:399–406.PubMed
23.
Dal Forno G, Carson KA, Brookmeyer R, Troncoso J, Kawas CH, et al. APOE genotype and survival in men and women with Alzheimer’s disease. Neurology. 2002;58:1045–50.
24.
Garcia-Ptacek S, Farahmand B, Kareholt I, Religa D, Cuadrado ML, et al. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis. 2014;41:467–77.PubMed
25.
Brehaut JC, Raina P, Lindsay J. Does cognitive status modify the relationship between education and mortality? Evidence from the Canadian Study of Health and Aging. Int Psychogeriatr. 2004;16:75–91.PubMed
26.
Andersen K, Lolk A, Martinussen T, Kragh-Sørensen P. Very mild to severe dementia and mortality: a 14-year follow-up - the Odense study. Dement Geriatr Cogn Disord. 2010;29:61–7.PubMed
27.
Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, et al. The National Alzheimer’s Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord. 2007;21:249–58.PubMed
28.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.PubMed
29.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
30.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.PubMed
31.
Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323–9.PubMed
32.
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233–9.PubMed
33.
Dafsari FS, Jessen F. Depression-an underrecognized target for prevention of dementia in Alzheimer’s disease. Transl Psychiatry. 2020;10:160.PubMedPubMedCentral
34.
Hanseeuw BJ, Jonas V, Jackson J, Betensky RA, Rentz DM, et al. Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry. 2020;25:2599–607.PubMed
35.
Green C, Zhang S. Predicting the progression of Alzheimer’s disease dementia: a multidomain health policy model. Alzheimers Dement. 2016;12:776–85.PubMedPubMedCentral
36.
Lee DR, Taylor JP, Thomas AJ. Assessment of cognitive fluctuation in dementia: a systematic review of the literature. Int J Geriatr Psychiatry. 2012;27:989–98.PubMed
37.
Roberts RO, Knopman DS, Mielke MM, Cha RH, Pankratz VS, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology. 2014;82:317–25.PubMedPubMedCentral
38.
Ferrari P, Licaj I, Muller DC, Kragh Andersen P, Johansson M, et al. Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and nutrition (EPIC) study. BMJ Open. 2014;4: e005245.PubMedPubMedCentral
39.
Jacobs DR Jr, Adachi H, Mulder I, Kromhout D, Menotti A, et al. Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study. Arch Intern Med. 1999;159:733–40.PubMed
40.
Fabbri E, Zoli M, Gonzalez-Freire M, Salive ME, Studenski SA, et al. Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. J Am Med Dir Assoc. 2015;16:640–7.PubMedPubMedCentral
41.
Grande G, Marengoni A, Vetrano DL, Roso-Llorach A, Rizzuto D, et al. Multimorbidity burden and dementia risk in older adults: the role of inflammation and genetics. Alzheimers Dement. 2021;17:768–76.PubMedPubMedCentral
42.
Herring WL, Gould IG, Fillit H, Lindgren P, Forrestal F, et al. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer’s disease. Neurol Ther. 2021;10:919–40.PubMedPubMedCentral
43.
Potashman M, Buessing M, LevitchiBenea M, Cummings J, Borson S, et al. Estimating progression rates across the spectrum of Alzheimer’s disease for amyloid-positive individuals using National Alzheimer’s Coordinating Center data. Neurol Ther. 2021;10:941–53.PubMedPubMedCentral
44.
O’Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer’s research consortium study. Arch Neurol. 2008;65:1091–5.PubMedPubMedCentral
45.
46.
Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, et al. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain. 2015;138:1327–38.PubMedPubMedCentral
47.
Vassilaki M, Cha RH, Aakre JA, Therneau TM, Geda YE, et al. Mortality in mild cognitive impairment varies by subtype, sex, and lifestyle factors: the Mayo Clinic Study of Aging. J Alzheimers Dis. 2015;45:1237–45.PubMedPubMedCentral
48.
Bae JB, Han JW, Kwak KP, Kim BJ, Kim SG, et al. Impact of mild cognitive impairment on mortality and cause of death in the elderly. J Alzheimers Dis. 2018;64:607–16.PubMed
49.
Contador I, Bermejo-Pareja F, Mitchell AJ, Trincado R, Villarejo A, et al. Cause of death in mild cognitive impairment: a prospective study (NEDICES). Eur J Neurol. 2014;21:253-e9.PubMed
50.
Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, et al. The Alzheimer’s Disease Centers’ Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009;23:91–101.PubMedPubMedCentral
51.
52.
53.
Arias E, Xu J. United States Life Tables, 2019. Natl Vital Stat Rep. 2022;70:1–59.PubMed
54.
Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012;71:266–73.PubMed
55.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.PubMed
56.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.PubMedPubMedCentral
57.
Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:257–62.PubMedPubMedCentral
Metadata
Title
Disease severity and mortality in Alzheimer's disease: an analysis using the U.S. National Alzheimer’s Coordinating Center Uniform Data Set
Authors
Valerie Crowell
Adriana Reyes
Summera Qiheng Zhou
Maria Vassilaki
Sandro Gsteiger
Anders Gustavsson
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03353-w

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue

Research article

Association of polygenic risk score with response to deep brain stimulation in Parkinson’s disease

Research

Short- and long-term outcomes of patients with minor stroke and nonvalvular atrial fibrillation

Research

Association between neutrophil-to-albumin ratio and long-term mortality of aneurysmal subarachnoid hemorrhage

Research

Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis

Case report

Lymphomatoid granulomatosis with the central nervous system involvement as the main manifestation: a case report

Research

Deep medullary veins: a promising neuroimaging marker for mild cognitive impairment in outpatients